The burgeoning popularity of semaglutide , initially for diabetes , is creating significant interest within the UK , prompting a notable shift in peptide trends. Obtaining these compounds remains a complex landscape, with NHS coverage currently limited and specialist practices offering prescriptions at a higher cost . Concerns are being raised rega